Table 2.
Major clinical characteristics of the recruited severe acute isolated optic neuritis patients with different serum AQP4-antibody status.
| Total | Serum AQP4-antibody
positive |
Serum AQP4-antibody
negative |
p c | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| All | Final Snellen VA ⩽ 20/40 | Final Snellen VA > 20/40 | p a | All | Final Snellen VA ⩽ 20/40 | Final Snellen VA > 20/40 | p b | |||
| Study subjects [eyes (n)] | 37 (37) | 20 (20) | 15 | 5 | – | 17 (17) | 12 | 5 | – | – |
| Onset age (mean ± SD, years) | 38.7 ± 14.8 | 42.0 ± 16.2 | 46.2 ± 15.3 | 29.3 ± 12.2 | 0.042 d | 34.8 ± 12.4 | 37.2 ± 12.4 | 28.9 ± 11.6 | 0.328d | 0.149d |
| BMI (mean ± SD, kg/m2) | 24.2 ± 4.2 | 23.5 ± 4.4 | 24.5 ± 4.5 | 20.4 ± 2.7 | 0.053d | 25.1 ± 3.7 | 26.0 ± 3.7 | 22.9 ± 3.1 | 0.130d | 0.167d |
| Gender (female, n) | 26 | 17 | 12 | 5 | 0.539e | 9 | 7 | 2 | 0.620e | 0.069e |
| Affected eye (bilateral, n) | 18 | 7 | 7 | 0 | 0.114e | 11 | 9 | 2 | 0.280e | 0.103e |
| MOG antibody status (n) | ||||||||||
| Positive | 1 | 0 | 0 | 0 | 1 | 0 | 1 | |||
| Negative | 23 | 12 | 8 | 4 | 0.603e | 11 | 7 | 4 | – | 0.472e |
| Unknown | 13 | 8 | 7 | 1 | 5 | 5 | 0 | |||
| Orbital MRI lesion (n) | ||||||||||
| Retrobulbar | 29 | 14 | 10 | 4 | >0.999e | 15 | 10 | 5 | >0.999e | 0.246e |
| Canalicular | 15 | 5 | 4 | 1 | >0.999e | 10 | 8 | 2 | 0.593e | 0.050e |
| Intracranial | 10 | 4 | 3 | 1 | >0.999e | 6 | 5 | 1 | 0.600e | 0.460e |
| Chiasmal involvement | 4 | 0 | 0 | 0 | – | 4 | 4 | 0 | 0.261e | 0.036 e |
| Longitudinally extensive optic nerve lesion | 33 | 16 | 12 | 4 | >0.999e | 17 | 12 | 5 | – | 0.109e |
| VA at onset (logMAR, mean ± SD) | 3.4 ± 1.5 | 3.1 ± 1.6 | 2.8 ± 1.7 | 4.1 ± 0.9 | 0.168d | 3.8 ± 1.3 | 3.5 ± 1.4 | 4.3 ± 0.9 | 0.328d | 0.297d |
| VA at final visit (logMAR, mean ± SD) | 1.7 ± 1.5 | 1.7 ± 1.5 | 1.6 ± 1.5 | 2.0 ± 1.7 | 0.612d | 1.6 ± 1.6 | 1.2 ± 1.3 | 2.4 ± 2.2 | 0.442d | 0.357d |
| Good final visual acuity outcome (VA > 20/40, n) | 10 | 5 | 0 | 5 | – | 5 | 0 | 5 | – | >999e |
| Onset to PE window (mean ± SD, days) | 27.2 ± 12.7 | 21.6 ± 12.6 | 23.5 ± 13.8 | 16.0 ± 6.1 | 0.349d | 33.9 ± 9.5 | 36.1 ± 8.0 | 28.8 ± 11.7 | 0.130d | 0.001 d |
a
p-value for comparison between final visual acuity (VA) outcomes in serum AQP4-antibody positive group.
b
p-value for comparison between final VA outcomes comparison in serum AQP4-antibody negative group.
c
p-value for comparison between serum AQP4-antibody positive and negative groups.
d
Mann–Whitney U test.
e
Fisher’s exact test.
Bold: p < 0.05.
AQP4, aquaporin-4; BMI, body mass index; logMAR, log of the minimum angle of resolution; MOG, myelin oligodendrocyte glycoprotein; MRI, magnetic resonance imaging; PE, plasma exchange; SD, standard deviation; VA, visual acuity.